Cargando…

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QT(c) interval in healthy subjects

AIMS: Exenatide has been demonstrated to improve glycaemic control in patients with type 2 diabetes, with no effect on heart rate corrected QT (QT(c)) at therapeutic concentrations. This randomized, placebo- and positive-controlled, crossover, thorough QT study evaluated the effects of therapeutic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darpö, Börje, Sager, Philip, MacConell, Leigh, Cirincione, Brenda, Mitchell, Malcolm, Han, Jenny, Huang, Wenying, Malloy, Jaret, Schulteis, Christine, Shen, Larry, Porter, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Science Inc 2013
Materias:	Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612716/ https://www.ncbi.nlm.nih.gov/pubmed/22882281 http://dx.doi.org/10.1111/j.1365-2125.2012.04416.x

Ejemplares similares

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
por: MacConell, Leigh, et al.
Publicado: (2015)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

Model‐Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion
por: Cirincione, Brenda, et al.
Publicado: (2017)

Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals
por: Darpo, Borje, et al.
Publicado: (2017)

Influence of Meals and Glycemic Changes on QT Interval Dynamics
por: Cirincione, Brenda, et al.
Publicado: (2017)

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell, Leigh, et al.
Publicado: (2013)

Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects
por: Ring, Arne, et al.
Publicado: (2013)

Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria
por: Darpo, Borje, et al.
Publicado: (2015)

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
por: Blonde, Lawrence, et al.
Publicado: (2015)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
por: MacConell, Leigh, et al.
Publicado: (2012)

Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
por: Borin, Marie T., et al.
Publicado: (2019)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects
por: Darpo, Borje, et al.
Publicado: (2019)

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects
por: Astruc, B, et al.
Publicado: (2017)

Potential strategy for assessing QT/QTc interval for drugs that produce rapid changes in heart rate: Electrocardiographic assessment of the effects of intravenous remimazolam on cardiac repolarization
por: Kleiman, Robert B., et al.
Publicado: (2020)

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
por: Diamant, Michaela, et al.
Publicado: (2012)

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
por: Mendzelevski, Boaz, et al.
Publicado: (2018)

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
por: Gill, Anne, et al.
Publicado: (2010)

Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects
por: Täubel, Jörg, et al.
Publicado: (2016)

Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
por: Darpo, Borje, et al.
Publicado: (2014)

Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
por: Darpo, Borje, et al.
Publicado: (2014)

Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study
por: Shen, Zancong, et al.
Publicado: (2016)

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer
por: Lush, Richard M., et al.
Publicado: (2012)

Diurnal QT analysis in patients with sotalol after cardioversion of atrial fibrillation
por: Lenhoff, Hanna, et al.
Publicado: (2021)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Effect of QT interval-prolonging drugs taken in pregnancy on the neonatal QT interval
por: Michel, Holger, et al.
Publicado: (2023)

A Randomized, Single‐Blind, Placebo‐Controlled, 3‐Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects
por: Shimizu, Hidetoshi, et al.
Publicado: (2020)

A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects
por: Abbas, Richat, et al.
Publicado: (2019)

Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors
por: Olszanski, Anthony J., et al.
Publicado: (2016)

Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men
por: Chen, Nianhang, et al.
Publicado: (2013)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects
por: Mu, Song, et al.
Publicado: (2020)

Beyond a prolonged QT interval
por: Bitar, Zouheir Ibrahim, et al.
Publicado: (2013)

Hydroxychloroquine-associated QT interval prolongation
Publicado: (2020)

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
por: Mueller, Markus S., et al.
Publicado: (2020)

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
por: Darpo, Borje, et al.
Publicado: (2023)

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist
por: Hoch, Matthias, et al.
Publicado: (2014)

Multifactorial QT Interval Prolongation and Takotsubo Cardiomyopathy
por: Gysel, Michael, et al.
Publicado: (2014)

QT interval prolongation with hydroxychloroquine plus azithromycin
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vl69qu2tafl01jq9durb2gai19